

cpt[®] **Assistant**

Official source for CPT coding guidance

SPECIAL EDITION: September Update

New COVID-19 Vaccine Codes: September Update

The Current Procedural Terminology (CPT[®]) Editorial Panel (the Panel) has approved two vaccine product codes (91312, 91315) and two vaccine administration codes (0124A, 0154A) for the new Pfizer bivalent booster vaccine to address severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019 [COVID-19]) for patients aged 12 years and older and in pediatric patients aged 5 through 11 years. In addition, the Panel has approved two vaccine product codes (91313, 91314) and two vaccine administration codes (0134A, 0144A) for the new Moderna bivalent booster vaccine to address COVID-19 for patients aged 18 years and older and in pediatric patients aged 6 through 11 years. These codes will become effective upon receiving the emergency use authorization (EUA) from the Food and Drug Administration (FDA).

In order to assist CPT code users in differentiating and appropriately reporting the available vaccine product codes and their affiliated immunization administration codes, the American Medical Association (AMA) established a website (<https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>) that features timely updates of the Panel's actions. The last COVID-19 update was in the *CPT[®] Assistant Special Edition: July Update* (2022) in which the Moderna vaccine administration codes (0091A, 0092A, 0093A) for pediatric patients aged 6 through 11 years, as well as the Moderna vaccine administration code (0013A) for pediatric patients aged 6 months through 5 years were discussed.

This issue of *CPT® Assistant Special Edition* provides guidance on the appropriate use of the new Pfizer bivalent vaccine product codes (91312, 91315) and vaccine administration codes (0124A, 0154A) for patients aged 12 years and older and patients aged 5 through 11 years, as well as the new Moderna bivalent vaccine product codes (91313, 91314) and vaccine administration codes (0134A, 0144A) for patients aged 18 years and older and patients aged 6 through 11 years.

Immunization Administration for Vaccines/Toxoids

- #● 0124A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose
- ▶ (Report 0124A for the administration of vaccine 91312) ◀
 - ▶ (Do not report 0124A in conjunction with 91300, 91305, 91307, 91308, 91315) ◀
- #● 0154A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose
- ▶ (Report 0154A for the administration of vaccine 90315) ◀
 - ▶ (Do not report 0154A in conjunction with 91300, 91305, 91307, 91308, 91312) ◀
- #● 0134A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose
- ▶ (Report 0134A for the administration of vaccine 91313) ◀

▶(Do not report 0134A in conjunction with 91301, 91306, 91309, 91311, 91314)◀

#● 0144A

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 25 mcg/0.25 mL dosage, booster dose

▶(Report 0144A for the administration of vaccine 91314)◀

▶(Do not report 0124A in conjunction with 91301, 91306, 91311, 91309, 91313)◀

Vaccines, Toxoids

#● 91312

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

▶(Report 91312 with administration codes 0124A)◀

▶(Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0154A)◀

#✎● 91315

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use

▶(Report 91315 with administration codes 0154A)◀

▶(Do not report 91315 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0124A)◀

91314

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use

▶ (Report 91314 with administration code 0144A) ◀

▶ (Do not report 91314 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0134A) ◀

91313

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use

▶ (Report 91313 with administration code 0134A) ◀

▶ (Do not report 91314 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0144A) ◀

New vaccine product codes 91312 and 91315 describe the new Pfizer bivalent COVID-19 vaccine product that will be made available as a booster dose for patients who were previously vaccinated for COVID-19. This new bivalent product targets both COVID-19 subvariants BA.4 and BA.5. The vaccine product described by code 91312 is available in a 30 mcg/0.3 mL dosage and may be used in patients aged 12 years and older. The vaccine product described by code 91315 is available in a 10 mcg/0.2 mL dosage and may be used in patients aged 5 through 11 years. Administration of these booster doses should be reported with administration codes 0124A and 0154A, respectively.

New vaccine product codes 91313 and 91314 describe the new Moderna bivalent COVID-19 vaccine. As with the Pfizer vaccine, this new bivalent vaccine product targets both COVID-19 subvariants BA.4 and BA.5 and may be used as a booster dose for patients who were previously vaccinated for COVID-19. The vaccine product described by code 91313 is available in a 50 mcg/0.5 mL dosage and may be used in patients aged 18 years and older. The vaccine product described by code 91314 is available in a 25 mcg/0.25 mL dosage and may be used in patients aged 6 through 11 years. Administration of these booster doses should be reported with administration codes 0134A and 0144A, respectively.

As with previous COVID-19 vaccine administration codes, counseling is included as part of the administration visit and should not be reported separately. The physician or other qualified health care professional (QHP) should exercise clinical judgment to determine whether the administration of the vaccine product is appropriate for a given patient. More information on current guidance from the Centers for Disease Control and Prevention (CDC) regarding which patients should receive a COVID-19 vaccine is available at <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html>.

Note that vaccine administration codes 0124A and 0154A are only intended to be reported with vaccine product codes 91312 and 91315, respectively, and vaccine administration codes 0134A and 0144A are only intended to be reported with vaccine product codes 91313 and 91314, respectively. Parenthetical notes have been added following these codes to clarify the appropriate use of these new codes.

To accommodate the new coding structure, Appendix Q was added to the CPT code set. Appendix Q details the vaccine codes, their associated vaccine administration code(s), the vaccine manufacturers and names, the National Drug Code (NDC) labeler product ID, and dosing intervals. Appendix Q was recently reformatted to also show appropriate age ranges for each vaccine product and the associated vaccine administration codes to assist in providing clarity for the user. The new vaccine product and administration codes discussed in this update will be added to Appendix Q.

Additional details on the new vaccine coding structure and other pertinent information provided in multiple special editions of the *CPT® Assistant* for COVID-19 guidance are available at <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance>.

Table 1 is an excerpt from Appendix Q that highlights the Pfizer and Moderna vaccine product codes and vaccine administration codes discussed in this article. Refer to the full text of Appendix Q, which is available at <https://www.ama-assn.org/system/files/covid-19-immunizations-appendix-q-table.pdf>, to keep abreast of additional changes as they occur.

Table 1 Excerpt from Appendix Q: New Pfizer and Moderna COVID-19 Vaccine Product and Administration Codes

Vaccine Code	Vaccine Administration Code(s)	Patient Age
#● 91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	● 0124A (Booster)	12 years and older

Vaccine Code	Vaccine Administration Code(s)	Patient Age
(coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use		
# 91315 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	● 0154A (Booster)	5 years through 11 years
# 91313 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	● 0134A (Booster)	18 years and older
# 91314 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	● 0144A (Booster)	6 years through 11 years

The following clinical examples and procedural descriptions reflect typical clinical scenarios for which these new codes would be appropriately reported.

Clinical Example (91312)

A 33-year-old individual seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (91312)

The physician or other qualified healthcare professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

Clinical Example (0124A)

A 33-year-old individual who was previously immunized with a primary series seeks booster immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (0124A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the patient on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the booster dose of the COVID-19 vaccine by intramuscular injection in the upper arm. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Clinical Example (91315)

A parent or guardian of a 7-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (91315)

The physician or other qualified healthcare professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

Clinical Example (0154A)

A parent or guardian of a 7-year-old child who was previously immunized with a primary series seeks booster immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (0154A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the patient on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the booster dose of the COVID-19 vaccine by intramuscular injection in the upper arm. Monitor the patient for any adverse

reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Clinical Example (91313)

A 33-year-old individual seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (91313)

The physician or other qualified healthcare professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

Clinical Example (0134A)

A 33-year-old individual who was previously immunized with a primary series seeks booster immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (0134A)

The physician or other QHP reviews the patient's chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the patient on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the booster dose of the COVID-19 vaccine by intramuscular injection in the upper arm. Monitor the patient for any adverse reaction. Update the patient's immunization record (and registry when applicable) to reflect the vaccine administered.

Clinical Example (91314)

A parent or guardian of a 7-year-old child seeks immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (91314)

The physician or other qualified healthcare professional (QHP) determines that the SARS-CoV-2 vaccine is appropriate for this patient and dispenses the vaccine according to the dose scheduled in the administration code for the SARS-CoV-2 vaccine.

Clinical Example (0144A)

A parent or guardian of a 7-year-old child who was previously immunized with a primary series seeks booster immunization against SARS-CoV-2 to decrease the risk of contracting this disease, consistent with evidence-supported guidelines. The individual is offered and accepts an intramuscular injection of SARS-CoV-2 vaccine for this purpose.

Description of Procedure (0144A)

The physician or other QHP reviews the patient’s chart to confirm that vaccination to decrease the risk of COVID-19 is indicated. Counsel the patient on the benefits and risks of vaccination to decrease the risk of COVID-19 and obtain consent. Administer the booster dose of the COVID-19 vaccine by intramuscular injection in the upper arm. Monitor the patient for any adverse reaction. Update the patient’s immunization record (and registry when applicable) to reflect the vaccine administered.

AMA Staff

Leslie W. Prellwitz, MBA, CCS, CCS-P, Managing Editor

Rejina Young, Editorial Assistant

Contributing Staff

Jennifer Bell; Kerri Fei; Karen O’Hara; Andrei G. Besleaga; Keisha Sutton-Asaya

Development and Production Staff

Elizabeth Goodman Duke; Lisa Chin-Johnson; Katharine Dvorak; Paige Downie

Orders: ama-assn.org/subscriptions

AMA website: www.ama-assn.org

The *CPT® Assistant Special Edition* information is designed to provide accurate, up-to-date coding information. We continue to make every reasonable effort to ensure the accuracy of the material presented. However, this publication does not replace the *CPT®* codebook; it serves only as a guide.

©2022 American Medical Association. All rights reserved. No part of this publication may be reproduced in any form without prior written permission of the publisher. *CPT®* is a registered trademark of the American Medical Association.